Home / Deep Research / Allergic Cutaneous Vasculitis

Allergic Cutaneous Vasculitis

Evidence gaps / limitations

2026-05-04
Falcon MONDO:0001290 Model: Edison Scientific Literature 23 citations

1. Disease Information

1.1 What is the disease? (concise overview)

ACV/CSVV/LCV is a small-vessel vasculitis of the skin in which inflammation primarily targets superficial dermal post-capillary venules, producing palpable purpura and related purpuric/urticarial lesions, most often on dependent areas (lower legs). It is typically immune-complex–mediated with complement activation, and may be idiopathic or triggered by drugs/infections; it can also reflect systemic vasculitis or systemic disease and thus requires evaluation for extracutaneous involvement. (micheletti2023cutaneoussmallvessel pages 1-2, micheletti2023cutaneoussmallvessel pages 2-5)

1.2 Key identifiers (ontology / coding)

  • MeSH: Vasculitis, Leukocytoclastic, Cutaneous — D018366 (NCT02550080 chunk 2)
  • ICD-10(-CM) codes used in large EHR research for LCV/cutaneous LCV: D69.0 and L95.8 (takatu2017clinicopathologiccorrelationof pages 1-2)
  • MONDO / Orphanet / OMIM: Not found in the retrieved sources; ACV/CSVV is generally treated as an acquired clinical-pathologic syndrome rather than a single-gene disorder in the dermatology/rheumatology literature summarized here. (micheletti2023cutaneoussmallvessel pages 1-2)

1.3 Common synonyms / alternative names

  • Cutaneous small-vessel vasculitis (CSVV)
  • Cutaneous leukocytoclastic vasculitis (LCV)
  • Leukocytoclastic vasculitis
  • Hypersensitivity vasculitis
  • Cutaneous leukocytoclastic angiitis (micheletti2023cutaneoussmallvessel pages 1-2)

1.4 Evidence sources

The information summarized here is derived from aggregated disease-level resources (reviews/guides) plus clinical cohorts/case series, not from a single EHR system except where explicitly noted (e.g., DIF cohort; population estimates; EHR database cohort). (micheletti2023cutaneoussmallvessel pages 5-6, fraticelli2021diagnosisandmanagement pages 1-2, takatu2017clinicopathologiccorrelationof pages 1-2)

2. Etiology

2.1 Disease causal factors (mechanistic)

The prevailing model is immune complex deposition in small cutaneous vessels with complement activation and neutrophil recruitment/activation, leading to vessel wall injury (fibrinoid necrosis), leukocytoclasia, and red blood cell extravasation (purpura). (micheletti2023cutaneoussmallvessel pages 1-2, fadel2025healthliteracyand pages 3-5)

2.2 Risk factors (clinical triggers and associated conditions)

Frequently reported triggers/associations include: - Medications (antibiotics, including beta-lactams, among common triggers) (micheletti2023cutaneoussmallvessel pages 2-5) - Infections (e.g., upper respiratory infections, Group A Streptococcus, hepatitis C) (micheletti2023cutaneoussmallvessel pages 2-5) - Systemic inflammatory/autoimmune disease (connective tissue diseases; ANCA-associated vasculitis; cryoglobulinemia; IgA vasculitis; urticarial vasculitis) (fraticelli2021diagnosisandmanagement pages 1-2) - Malignancy (less common): LCV may rarely be a paraneoplastic clue; reviews emphasize malignancy as a possible association that should be considered based on clinical context. (micheletti2023cutaneoussmallvessel pages 2-5, fraticelli2021diagnosisandmanagement pages 1-2)

2.3 Protective factors

No specific genetic or environmental protective factors were identified in the retrieved sources.

2.4 Gene–environment interactions

Not well defined for ACV/CSVV specifically in the retrieved sources. Mechanistically, type III immune complex reactions are driven by antigen exposure (infection/drug antigen) leading to immune-complex formation and complement activation. (fadel2025healthliteracyand pages 3-5, sunderkotter2023pathophysiologyandclinical pages 2-3)

3. Phenotypes

3.1 Core cutaneous phenotypes (with HPO suggestions)

Common skin manifestations (adult and pediatric literature overlap, but this report emphasizes adult CSVV/LCV): - Palpable purpura (dependent distribution, often lower legs) — suggested HPO: Purpura (HP:0000979) (micheletti2023cutaneoussmallvessel pages 1-2) - Petechiae / non-blanching purpura — suggested HPO: Petechiae (HP:0000967) (micheletti2023cutaneoussmallvessel pages 2-5) - Urticarial papules / wheals (esp. in urticarial vasculitis overlap) — suggested HPO: Urticaria (HP:0001025) (rothermel2024managingurticarialvasculitis pages 1-2) - Hemorrhagic vesicles/pustules (subset) — suggested HPO: Vesicle (HP:0001598) / Pustule (HP:0000966) (micheletti2023cutaneoussmallvessel pages 1-2) - Ulceration/necrosis/retiform purpura may indicate more severe disease or larger-vessel involvement and triggers expanded systemic evaluation — suggested HPO: Skin ulcer (HP:0001059) / Skin necrosis (HP:0025478) (micheletti2023cutaneoussmallvessel pages 2-5)

Extracutaneous symptoms (when present): - Arthralgia is commonly reported among extracutaneous symptoms — suggested HPO: Arthralgia (HP:0002829) (escamilla2024vasculitisleucocitoclásticaasociada pages 10-15)

3.2 Phenotype characteristics

3.3 Quality of life impact

Recent guidance emphasizes that cutaneous vasculitis can significantly impact patients and that management can be challenging despite skin-limited disease. (micheletti2023cutaneoussmallvessel pages 1-2)

4. Genetic / Molecular Information

4.1 Causal genes / pathogenic variants

Not established for typical ACV/CSVV: the retrieved clinical guidance treats CSVV/LCV largely as an acquired immune-mediated syndrome rather than a monogenic disorder. (micheletti2023cutaneoussmallvessel pages 1-2, fraticelli2021diagnosisandmanagement pages 1-2)

4.2 Modifier genes / epigenetics / chromosomal abnormalities

Not identified in the retrieved sources for ACV/CSVV.

Important “genetic mimic” note (clinical differential): monogenic autoinflammatory diseases can present with cutaneous vasculitis phenotypes in other contexts, but specific gene-level evidence for ACV/CSVV was not extracted from the retrieved texts in this run. (fraticelli2021diagnosisandmanagement pages 1-2)

5. Environmental Information

5.1 Environmental and lifestyle factors

No specific pollutant/toxin/lifestyle risks were identified in the retrieved sources, beyond exposure to triggering antigens such as medications and infections. (micheletti2023cutaneoussmallvessel pages 2-5)

5.2 Infectious agents

Upper respiratory infections, Group A Streptococcus, and hepatitis C are highlighted as common or notable triggers/associations in CSVV/LCV reviews. (micheletti2023cutaneoussmallvessel pages 2-5)

6. Mechanism / Pathophysiology

6.1 Causal chain (trigger → lesion)

A widely used mechanistic chain for immune-complex (type III) cutaneous vasculitis is: 1) Antigen exposure → 2) IgG formation and immune complex formation → 3) Immune complex deposition → 4) Classical complement cascade activation (C3a/C5a generation) → 5) mast cell degranulation and histamine release → 6) neutrophil recruitment and degranulation → 7) fibrinoid necrosis of vessel walls and leukocytoclasia → 8) RBC extravasation causing non-blanching purpura. (fadel2025healthliteracyand pages 3-5)

6.2 Immune-complex vasculitis and NETosis (recent developments)

A 2023 synthesis of immune-complex vasculitides highlights polymorphonuclear neutrophil activation via Fc receptors and notes that in IgA vasculitis, intravascular priming of neutrophils can lead to vessel-destructive NETosis upon encountering deposited IgA at vessel walls, linking Fcα receptor biology to NET formation and vascular injury. (sunderkotter2023pathophysiologyandclinical pages 1-2)

A 2024 pathology-focused review emphasizes that newer insights (including NETosis) are increasingly integrated into understanding of vasculitis initiation and progression. (cassisa2024cutaneousvasculitisinsights pages 1-2)

6.3 Key cellular players (CL term suggestions)

6.4 Key pathways and processes (GO term suggestions)

6.5 Tissue damage mechanism

Histopathologic injury includes fibrinoid necrosis of small vessels with neutrophilic infiltration and nuclear debris (leukocytoclasia), which can be visualized on H&E sections. (escamilla2024vasculitisleucocitoclásticaasociada pages 10-15, cassisa2024cutaneousvasculitisinsights media af7d9316)

7. Anatomical Structures Affected

7.1 Organ/tissue level

UBERON suggestions: - Skin — UBERON:0002097 - Dermis — UBERON:0002067

8. Temporal Development

8.1 Onset and course

9. Inheritance and Population

9.1 Epidemiology (recently summarized statistics)

A highly cited clinical review reports wide variability in reported epidemiology for biopsy-proven cutaneous LCV: - Incidence: 15–38 per million/year - Prevalence: 2.7–29.7 per million - A U.S. population study estimate for biopsy-proven LCV: 4.5 per 100,000 person-years (95% CI 3.5–5.4) (fraticelli2021diagnosisandmanagement pages 1-2)

9.2 Demographics

Cutaneous LCV affects both sexes and all ages; some studies report a slight male/older-age predilection. (fraticelli2021diagnosisandmanagement pages 2-3)

9.3 Inheritance

No Mendelian inheritance pattern is established for typical ACV/CSVV in the retrieved sources (acquired immune-mediated condition). (micheletti2023cutaneoussmallvessel pages 1-2)

10. Diagnostics

10.1 Clinical approach (real-world implementation)

A recent practical guide emphasizes history, exam, and review of systems to identify triggers and to distinguish skin-limited disease from systemic vasculitis. A targeted stepwise workup is favored, with broad testing reserved for systemic features. (micheletti2023cutaneoussmallvessel pages 2-5, micheletti2023cutaneoussmallvessel pages 5-6)

10.2 Laboratory tests (core and extended)

Minimal baseline tests for straightforward, skin-limited presentations (per dermatology guidance): - CBC - Basic metabolic panel / renal function - Urinalysis with microscopic review (screen for occult glomerulonephritis) (micheletti2023cutaneoussmallvessel pages 2-5)

Commonly used broader evaluation (particularly if systemic involvement is suspected): - Platelet count - Hepatitis B and C serologies - ANA and ANCA - Complement fractions - IgA staining in biopsy specimens (fraticelli2021diagnosisandmanagement pages 1-2)

10.3 Biopsy and immunopathology

10.4 Differential diagnosis

Key systemic associations to consider include ANCA-associated vasculitis, connective tissue diseases (e.g., SLE), cryoglobulinemic vasculitis, IgA vasculitis, and hypocomplementemic urticarial vasculitis. (fraticelli2021diagnosisandmanagement pages 1-2)

11. Outcome / Prognosis

11.1 Overall prognosis

A practical dermatology guide reports a generally favorable course: - ~90% resolve spontaneously within weeks to months - ~10% develop a chronic/relapsing course that may last months to years (micheletti2023cutaneoussmallvessel pages 6-7)

11.2 Prognostic factors (clinical)

Prognosis depends strongly on whether disease is skin-limited versus reflecting a systemic vasculitis/systemic disease, emphasizing the importance of accurate classification and systemic screening. (micheletti2023cutaneoussmallvessel pages 6-7)

12. Treatment

12.1 Treatment principles (current practice)

12.2 Common systemic therapies and dosing (real-world implementation)

From a 2023 practical guide: - Colchicine: 0.6 mg twice daily - Dapsone: 100–150 mg/day (screen for G6PD deficiency) - Azathioprine: target 2 mg/kg/day (screen TPMT) (micheletti2023cutaneoussmallvessel pages 5-6)

Oral glucocorticoids may be used for severe symptomatic disease (example regimens): - Prednisone ~0.5–1 mg/kg/day or 40–60 mg/day, tapered over 3–4 weeks; not appropriate as a long-term plan due to toxicity. (micheletti2023cutaneoussmallvessel pages 5-6, micheletti2023cutaneoussmallvessel pages 6-7)

Escalation options for refractory disease include mycophenolate mofetil, methotrexate, hydroxychloroquine, pentoxifylline, and (for severe refractory cases) rituximab, infliximab, IVIG, cyclosporine, cyclophosphamide. (micheletti2023cutaneoussmallvessel pages 5-6, micheletti2023cutaneoussmallvessel pages 6-7)

12.3 Trials / experimental evidence

  • ARAMIS trial (ongoing at the time of the guide): international randomized trial for colchicine in CSVV/LCV (ClinicalTrials.gov identifier NCT02939573) was cited as ongoing in the 2023 guide. (micheletti2023cutaneoussmallvessel pages 5-6)
  • Additional vasculitis-related observational/interventional trials relevant to immune-complex vasculitis phenotyping and relapse prevention include studies comparing IgA-positive vs IgA-negative immune complex vasculitis (NCT01815190) and adult IgA vasculitis relapse prevention with colchicine (NCT04008316). (NCT01815190 chunk 1, NCT04008316 chunk 2)

MAXO suggestions (treatment actions): - Systemic glucocorticoid therapy — MAXO:0000058 - Colchicine therapy — MAXO:0000745 (drug-based action; placeholder mapping) - Dapsone therapy — MAXO:0000746 (placeholder mapping) - Skin biopsy — MAXO:0000476 (diagnostic action; placeholder mapping)

Note: MAXO IDs above are suggested conceptually; confirm exact MAXO mappings in ontology tooling.

13. Prevention

13.1 Primary prevention

Primary prevention is not well defined for idiopathic CSVV. Practical prevention focuses on avoiding re-exposure to known culprit drugs and managing infections that have triggered prior episodes. (micheletti2023cutaneoussmallvessel pages 2-5, fraticelli2021diagnosisandmanagement pages 1-2)

13.2 Secondary/tertiary prevention

14. Other Species / Natural Disease

No veterinary/natural disease evidence was identified in the retrieved sources.

15. Model Organisms

No model organism systems specific to ACV/CSVV were identified in the retrieved sources.

Key figure (histopathology)

Representative histopathologic appearances of leukocytoclastic vasculitis (neutrophils infiltrating vessel wall with fibrin rim and leukocytoclasia/nuclear dust) are shown in a recent pathology review. (cassisa2024cutaneousvasculitisinsights media af7d9316)

Condensed knowledge-base table

Table (click to expand)
Preferred term + synonyms Key identifiers / codes Core clinical phenotype Recommended initial labs Biopsy / DIF key points Common triggers / associations Epidemiology / prognosis Treatment (first-line → escalation; typical doses)
Preferred term: cutaneous small-vessel vasculitis (CSVV), often used interchangeably with cutaneous leukocytoclastic vasculitis / leukocytoclastic vasculitis; older names include hypersensitivity vasculitis and cutaneous leukocytoclastic angiitis. "Allergic cutaneous vasculitis" is best mapped to this acquired, usually immune-complex-mediated skin-limited vasculitis category. (micheletti2023cutaneoussmallvessel pages 1-2, micheletti2023cutaneoussmallvessel pages 6-7) MeSH: Vasculitis, Leukocytoclastic, Cutaneous D018366. ICD-10-CM codes used in recent database work: D69.0 and L95.8 for LCV/cutaneous LCV. Formal OMIM/Orphanet/MONDO identifiers were not identified in the retrieved sources. (NCT02550080 chunk 2, NCT01815190 chunk 1) Typical lesions are palpable purpura, petechiae, urticarial papules, hemorrhagic vesicles/pustules, favoring dependent areas/lower legs; non-blanching purpura reflects RBC extravasation, and arthralgia is a common extracutaneous symptom. Lower-limb-only involvement was 80% in one 75-patient series; palpable purpura occurred in 64%. (micheletti2023cutaneoussmallvessel pages 1-2, micheletti2023cutaneoussmallvessel pages 2-5) For straightforward skin-limited disease with negative review of systems, suggested baseline tests are CBC, basic metabolic panel/renal function, and urinalysis with microscopy to screen for occult glomerulonephritis; broader workup may include ANA, ANCA, hepatitis B/C serologies, complement fractions, platelet count, and IgA staining when indicated. (micheletti2023cutaneoussmallvessel pages 2-5, fraticelli2021diagnosisandmanagement pages 1-2, fadel2025healthliteracyand pages 3-5) Skin biopsy is central: best from a new lesion (ideally 24–48 h old; ~1–2 days old). Histology shows neutrophilic small-vessel inflammation, leukocytoclasia, fibrinoid necrosis, and erythrocyte extravasation. DIF is recommended; one cohort found positivity in 70.21%, and Micheletti notes DIF is ~80% sensitive/specific for IgA vasculitis. (micheletti2023cutaneoussmallvessel pages 1-2, takatu2017clinicopathologiccorrelationof pages 1-2, escamilla2024vasculitisleucocitoclásticaasociada pages 10-15) Often idiopathic, but common triggers include medications (especially beta-lactams/other antibiotics), infections (notably upper respiratory infections, Group A Streptococcus, hepatitis C), and less often connective tissue disease, cryoglobulinemia, or malignancy. In one retrospective series, the most common secondary causes were infections and drugs. (micheletti2023cutaneoussmallvessel pages 2-5, fraticelli2021diagnosisandmanagement pages 1-2, fraticelli2021diagnosisandmanagement pages 2-3) Reported incidence ranges 15–38 cases per million/year with prevalence 2.7–29.7 per million; a U.S. population study estimated 4.5 per 100,000 person-years for biopsy-proven LCV. Most episodes are self-limited: 3–4 weeks for many cases; about 90% resolve spontaneously within weeks to months, while about 10% become chronic/relapsing. (fraticelli2021diagnosisandmanagement pages 2-3, fraticelli2021diagnosisandmanagement pages 1-2, micheletti2023cutaneoussmallvessel pages 6-7, micheletti2023cutaneoussmallvessel pages 5-6) Supportive/trigger removal first: rest, leg elevation, compression, topical steroids/NSAIDs where appropriate; stop culprit drug/treat infection. For symptomatic or recurrent disease: colchicine 0.6 mg BID, dapsone 100–150 mg/day (check G6PD), azathioprine target 2 mg/kg/day (check TPMT), prednisone ~0.5–1 mg/kg/day or 40–60 mg/day tapered over 3–4 weeks. Escalation for refractory/severe disease: mycophenolate 2–3 g/day, methotrexate 15–25 mg/week, hydroxychloroquine 200–400 mg/day, pentoxifylline 400 mg TID, and in severe refractory cases rituximab, infliximab, IVIG, cyclosporine, cyclophosphamide. (micheletti2023cutaneoussmallvessel pages 5-6, micheletti2023cutaneoussmallvessel pages 6-7, escamilla2024vasculitisleucocitoclásticaasociada pages 10-15, micheletti2023cutaneoussmallvessel pages 2-5)

Table: This table condenses the most useful disease-knowledge-base facts for allergic cutaneous vasculitis treated as cutaneous small-vessel/leukocytoclastic vasculitis. It captures nomenclature, identifiers, diagnostic workup, pathology, epidemiology, and practical treatment dosing in one place.

Direct abstract quotes (for key KB statements)

1) Definition / histology: “Leukocytoclastic vasculitis (LCV) is a histopathologic description of a common form of small vessel vasculitis (SVV)… the inflammatory infiltrate is composed of neutrophils with fibrinoid necrosis and disintegration of nuclei into fragments (“leukocytoclasia”).” (Fraticelli 2021; abstract excerpt) (fraticelli2021diagnosisandmanagement pages 1-2) 2) Mechanism / associations / workup: “Several medications can cause LCV, as well as infections, or malignancy… platelet count, renal function and urinalysis… hepatitis B and C… autoantibodies (anti-nuclear… anti-neutrophil cytoplasmic antibodies), complement fractions and IgA staining in biopsy specimens are part of the usual workout of LCV.” (Fraticelli 2021; abstract excerpt) (fraticelli2021diagnosisandmanagement pages 1-2) 3) Type III hypersensitivity: “Serum sickness and CV fulfill the criteria of a type III hypersensitivity immune reaction…” (Sunderkötter 2023; abstract excerpt) (sunderkotter2023pathophysiologyandclinical pages 1-2)

Evidence gaps / limitations

  • MONDO/Orphanet/OMIM identifiers were not present in the retrieved document set and thus are not reported here.
  • High-quality randomized trial evidence for CSVV/LCV treatments remains limited; recent guides emphasize reliance on case series and expert opinion with ongoing trial efforts (e.g., colchicine). (micheletti2023cutaneoussmallvessel pages 5-6)

References

  1. (micheletti2023cutaneoussmallvessel pages 1-2): Robert G. Micheletti. Cutaneous small vessel vasculitis: a practical guide to diagnosis and management. American Journal of Clinical Dermatology, 24:89-95, Oct 2023. URL: https://doi.org/10.1007/s40257-022-00736-6, doi:10.1007/s40257-022-00736-6. This article has 15 citations and is from a peer-reviewed journal.

  2. (micheletti2023cutaneoussmallvessel pages 5-6): Robert G. Micheletti. Cutaneous small vessel vasculitis: a practical guide to diagnosis and management. American Journal of Clinical Dermatology, 24:89-95, Oct 2023. URL: https://doi.org/10.1007/s40257-022-00736-6, doi:10.1007/s40257-022-00736-6. This article has 15 citations and is from a peer-reviewed journal.

  3. (cassisa2024cutaneousvasculitisinsights pages 1-2): Angelo Cassisa and Luca Cima. Cutaneous vasculitis: insights into pathogenesis and histopathological features. Pathologica, 116:119-133, Apr 2024. URL: https://doi.org/10.32074/1591-951x-985, doi:10.32074/1591-951x-985. This article has 11 citations.

  4. (sunderkotter2023pathophysiologyandclinical pages 1-2): Cord Sunderkötter, Linda Golle, Evangéline Pillebout, and Christiane Michl. Pathophysiology and clinical manifestations of immune complex vasculitides. Frontiers in Medicine, Mar 2023. URL: https://doi.org/10.3389/fmed.2023.1103065, doi:10.3389/fmed.2023.1103065. This article has 27 citations.

  5. (micheletti2023cutaneoussmallvessel pages 2-5): Robert G. Micheletti. Cutaneous small vessel vasculitis: a practical guide to diagnosis and management. American Journal of Clinical Dermatology, 24:89-95, Oct 2023. URL: https://doi.org/10.1007/s40257-022-00736-6, doi:10.1007/s40257-022-00736-6. This article has 15 citations and is from a peer-reviewed journal.

  6. (NCT02550080 chunk 2): Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome. Shandong Provincial Institute of Dermatology and Venereology. 2015. ClinicalTrials.gov Identifier: NCT02550080

  7. (takatu2017clinicopathologiccorrelationof pages 1-2): Caroline Maris Takatu, Antonio Pedro Ribeiro Heringer, Valéria Aoki, Neusa Yuriko Sakai Valente, Paula Cristina de Faria Sanchez, Jozélio Freire de Carvalho, and Paulo Ricardo Criado. Clinicopathologic correlation of 282 leukocytoclastic vasculitis cases in a tertiary hospital: a focus on direct immunofluorescence findings at the blood vessel wall. Immunologic Research, 65:395-401, Feb 2017. URL: https://doi.org/10.1007/s12026-016-8850-6, doi:10.1007/s12026-016-8850-6. This article has 33 citations and is from a peer-reviewed journal.

  8. (fraticelli2021diagnosisandmanagement pages 1-2): Paolo Fraticelli, Devis Benfaremo, and Armando Gabrielli. Diagnosis and management of leukocytoclastic vasculitis. Internal and Emergency Medicine, 16:831-841, Mar 2021. URL: https://doi.org/10.1007/s11739-021-02688-x, doi:10.1007/s11739-021-02688-x. This article has 215 citations and is from a peer-reviewed journal.

  9. (fadel2025healthliteracyand pages 3-5): Lynn Fadel, Sara Shah, Jehad Feras AlSamhori, Justin Ma, Ahmed Nadeem-Tariq, Janae Rasmussen, Kiratpreet Sraa, and Kelly Frasier. Health literacy and treatment adherence in patients with cutaneous-limited vasculitis and musculoskeletal pain. ARC Journal of Dermatology, 8:21-37, Jan 2025. URL: https://doi.org/10.20431/2456-0022.0807003, doi:10.20431/2456-0022.0807003. This article has 0 citations.

  10. (sunderkotter2023pathophysiologyandclinical pages 2-3): Cord Sunderkötter, Linda Golle, Evangéline Pillebout, and Christiane Michl. Pathophysiology and clinical manifestations of immune complex vasculitides. Frontiers in Medicine, Mar 2023. URL: https://doi.org/10.3389/fmed.2023.1103065, doi:10.3389/fmed.2023.1103065. This article has 27 citations.

  11. (rothermel2024managingurticarialvasculitis pages 1-2): Nikolai Dario Rothermel, Carolina Vera Ayala, Margarida Gonçalo, Jie Shen Fok, Leonie Shirin Herzog, Emek Kocatürk, Sophia Neisinger, Manuel P. Pereira, Indrashis Podder, Polina Pyatilova, Aiste Ramanauskaite, Melba Munoz, Karoline Krause, Marcus Maurer, Hanna Bonnekoh, and Pavel Kolkhir. Managing urticarial vasculitis: a clinical decision-making algorithm based on expert consensus. American Journal of Clinical Dermatology, 26:61-75, Nov 2024. URL: https://doi.org/10.1007/s40257-024-00902-y, doi:10.1007/s40257-024-00902-y. This article has 14 citations and is from a peer-reviewed journal.

  12. (escamilla2024vasculitisleucocitoclásticaasociada pages 10-15): Diana Verónica Romero Escamilla, Mariam Hussein Jumaan Torres, and Julieta Peralta y Serna. Vasculitis leucocitoclástica asociada a infección: a proposito de un caso y revisión de literatura. Revista Científica de Salud y Desarrollo Humano, 5:177-190, Oct 2024. URL: https://doi.org/10.61368/r.s.d.h.v5i4.345, doi:10.61368/r.s.d.h.v5i4.345. This article has 2 citations.

  13. (cassisa2024cutaneousvasculitisinsights media af7d9316): Angelo Cassisa and Luca Cima. Cutaneous vasculitis: insights into pathogenesis and histopathological features. Pathologica, 116:119-133, Apr 2024. URL: https://doi.org/10.32074/1591-951x-985, doi:10.32074/1591-951x-985. This article has 11 citations.

  14. (micheletti2023cutaneoussmallvessel pages 6-7): Robert G. Micheletti. Cutaneous small vessel vasculitis: a practical guide to diagnosis and management. American Journal of Clinical Dermatology, 24:89-95, Oct 2023. URL: https://doi.org/10.1007/s40257-022-00736-6, doi:10.1007/s40257-022-00736-6. This article has 15 citations and is from a peer-reviewed journal.

  15. (fraticelli2021diagnosisandmanagement pages 2-3): Paolo Fraticelli, Devis Benfaremo, and Armando Gabrielli. Diagnosis and management of leukocytoclastic vasculitis. Internal and Emergency Medicine, 16:831-841, Mar 2021. URL: https://doi.org/10.1007/s11739-021-02688-x, doi:10.1007/s11739-021-02688-x. This article has 215 citations and is from a peer-reviewed journal.

  16. (NCT01815190 chunk 1): Cord Sunderkötter. IgA-positive Versus IgA-negative Immune Complex Vasculitis. University Hospital Muenster. 2011. ClinicalTrials.gov Identifier: NCT01815190

  17. (NCT04008316 chunk 2): Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis. Assistance Publique - Hôpitaux de Paris. 2019. ClinicalTrials.gov Identifier: NCT04008316